Post-treatment Prostate Biopsies in the Era of Three-Dimensional Conformal Radiotherapy: What Can They Teach Us?

European Urology

Volumn 55, Issue 4, 2009, Pages 902-910

  Zapatero, Almudena ^a   Mínguez, Ricardo ^a   Nieto, Santiago ^a   Martín de Vidales, Carmen ^a   García Vicente, Feliciano ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Androgen deprivation; Conformal radiotherapy; Postradiation biopsies; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CLINICAL ASSESSMENT; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 60249102090     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.076     Document Type: Article

References (24)

1. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355-367
4. Kestin L.L., Goldstein N.S., Vicini F.A., et al. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiation Oncology Biol Phys 54 (2002) 107-118
5. Weinstein M.H., Signoretti S., and Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 15 (2002) 1302-1308
6. Zapatero A., Rios P., Marin A., Miguez R., and Garcia-Vicente F. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?. Clin Oncol (R Coll Radiol) 18 (2006) 600-607
7. American Society for Therapeutic Radiology, Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
8. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
9. D'Amico A.V., Whittington R., Malkowicz S.B., et al. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32 (1995) 473-477
10. Vicini F.A., Kestin L.L., and Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 553-561
11. Connell P.P., Ignacio L., McBride R.B., et al. Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology 54 (1999) 875-879
12. Kestin L.L., Vicini F.A., and Martinez A.A. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 53 (2002) 304-315
13. Crook J.M., Perry G.A., Robertson S., et al. Routine prostate biopsies following adiotherapy for prostate cancer: results for 226 patients. Urology 45 (1995) 624-631
14. Gaudin P.B., Zelefsky M.J., Leibel S.A., et al. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 23 (1999) 1021-1031
15. Prestidge B.R., Hoak D.C., Grimm P.D., et al. Posttreatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 31-39
16. Crook J.M., Bahadur Y.A., Robertson S.J., et al. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 79 (1997) 81-89
17. Nichol A., Chung P., Lockwood G., et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
18. Mackey T.J., Borkowski A., Amin P., et al. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52 (1998) 1085-1090
19. Di Lorenzo G., De Placido S., Autorino R., et al. Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease. Prostate Cancer Prostatic Dis 8 (2005) 54-59
20. Amirghofran Z., Monabati A., and Gholijani N. Apoptosis in prostate cancer: bax correlation with stage. Int J Urol 12 (2005) 340-345
21. Pollack A., Cowen D., Troncoso P., et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97 (2003) 1630-1638
22. Li R., Heydon K., Hammond M.E., et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. Clin Cancer Res 10 (2004) 4118-4124
23. Pollack A., DeSilvio M., Khor L.Y., et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22 (2004) 2133-2140
24. Ritter M., Gilchrist K.W., Voytovich M., Chappell R., and Verhoven B. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 574-580